A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Trial Profile

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs MOR 208 (Primary)
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors MorphoSys
  • Most Recent Events

    • 09 Aug 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2019.
    • 09 Aug 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Feb 2019.
    • 06 Dec 2016 Results of subgroup analysis from DLBCL and iNHL cohorts presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top